PD-L1 immunohistochemical assays for assessment of therapeutic strategies involving immune checkpoint inhibitors in non-small cell lung cancer: a comparative study

This publication has 21 references indexed in Scilit:

• Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer
  Seminars in Oncology, 2015
• Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status
  Laboratory Investigation, 2015
• Reliability of Small Biopsy Samples Compared With Resected Specimens for the Determination of Programmed Death-Ligand 1 Expression in Non–Small-Cell Lung Cancer
  Clinical Lung Cancer, 2015
• Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
  New England Journal of Medicine, 2015
• Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art?
  Journal of Thoracic Oncology, 2015
• Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
  New England Journal of Medicine, 2015
• PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
  Molecular Cancer Therapeutics, 2015
• Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
  Nature, 2014
• Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
  New England Journal of Medicine, 2012
• Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
  New England Journal of Medicine, 2012